SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli (Losartan Potassium)

Why It Matters

The move signals potential revenue upside for the company and increased competition in losartan formulations.

Summary

SCIENTURE has begun commercial sales and fulfilled first orders for Arbli (losartan potassium), positioning the product as the first FDA‑approved ready‑to‑use oral suspension for losartan. The company has launched a multi‑channel promotional campaign to drive adoption into a U.S. losartan market worth about $256 million annually with roughly 71 million prescriptions. SCIENTURE’s entry targets convenience and adherence benefits for patients and caregivers, and could capture share in a large, established market if uptake follows the promotional push. The move signals potential revenue upside for the company and increased competition in losartan formulations.